Irish plant for Wuxi Biologics
Print Edition
HONG Kong-listed biopharma technology service provider Wuxi Biologics will invest 325 million euros (US$390 million) for a new biologics drug manufacturing facility in Ireland, the first overseas investment of its kind for a Chinese pharma company.
The 260,000-square-meter manufacturing site will be located at an industrial park in Dundalk in northern Ireland and is expected to create 400 new jobs and 700 construction jobs in phases over five years.
The site will begin construction in the first quarter in 2019 and be complete by the second quarter of 2021.
“Wuxi Biologics is a strong addition to Ireland’s growing cluster of next-generation bio-pharmaceutical companies and it also shows great commitment to Ireland with this project,” said Martin Shanahan, CEO of the Industrial Development Authority of Ireland, on Monday.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
